Richard K. Kim

Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA.

Synedgen, Inc. operates as a biotechnology company leveraging a proprietary glycomics technology platform to develop modified therapeutic polysaccharides that target mucosal surfaces in genetic and acquired disorders. The firm’s products include Prisyna oral care and Synedgen wound care. The company was founded by William P. Wiesmann and Shenda Baker in 2009 and is headquartered in Claremont, CA.

Epirium Bio, Inc. develops therapeutics for orphan and rare diseases characterized by impairment of the skeletal muscle, cardiac and neuronal systems. The company was founded in 2008 by Alan Stewart Maisel, Sundeep Dugar, and Francisco Villarreal and is headquartered in Los Altos Hills, CA.

Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001.

The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

The Biotechnology Institute is a non-profit organization, which engages in designing and managing programs about biotechnology research. Its programs include BioGENEius Challenges, leadership awards, and Adopt-A-School. The company was founded in 1998 and is headquartered in Washington, DC.

Omniox, Inc. operates as a biopharmaceutical company which develops medicines for hypoxic diseases. Its technology overcomes fundamental biochemical shortcomings of hemoglobin-based and per fluorocarbon oxygen delivery approaches. The company was founded in 2006 by Stephen P. L. Cary, Michael A. Marletta, Jonathan Winger and Elizabeth Marshall Boon and is headquartered in San Carlos, CA.

Modern Meadow, Inc. design and produces biologically advanced materials. The firm produces Zoa, a branded materials platform constructed from biologically produced collagen protein. The company was founded by Francoise Marga, Karoly Jakab, and Gabor Forgacs in 2011 and is headquartered in Nutley, NJ.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA.

Mc2 Therapeutics is a Danish commercial stage biotech company that focuses on developing novel treatment paradigms for immune-mediated and inflammatory diseases. Mc2 Therapeutics is based in Denmark, specifically in Hørsholm, and has subsidiaries in the United Kingdom. The company is privately held and is developing a new standard of topical therapies for chronic inflammatory conditions using PAD™ technology. The company aims to release the full potential of novel topical drugs for the benefit of patients, physicians, payers, and societies.

EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA.

Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016.

RBNC Therapeutics, Inc. develops and commercializes therapies for individuals with brain diseases.

Happy Health, Inc. is a mission-driven technology company founded in 2019 and based in - that is committed to transforming mental health awareness. The company is based in Austin, TX and has subsidiaries in the United States. The company has developed the Happy Ring, which is the first wearable for your mind. The Happy Ring measures your stress and mood 24/7, providing real-time mood tracking that can change your life.

Elephas Biosciences Corp. is a live tumor imaging company that provides cancer diagnostic solutions to predict treatment outcomes and accelerate drug development. The company is based in Madison, WI and was founded by Maneesh K. Arora, who has been the CEO since incorporation. The company's revolutionary diagnostic platform brings insights to cancer treatment decisions and accelerates immuno-oncology drug development. Investors can learn about clinical trials aimed at predicting responses to immunotherapy and how immunotherapeutic drug development can be accelerated with Elephas Biosciences's cybrid.

Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials.

Human Immunology Biosciences, Inc. is a company based in South San Francisco, CA. Human Immunology Biosciences, Inc. was founded by Travis Murdoch, who has been the CEO since incorporation.